Drug Profile

EBX 102 02

Alternative Names: EBX-102-02

Latest Information Update: 19 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EnteroBiotix
Class Anti-inflammatories
Mechanism of Action Microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Irritable bowel syndrome; Transplant rejection

Most Recent Events

10 Mar 2026 EnteroBiotix completes enrolment in the phase II MAST trial in Transplant rejection (Prevention) in United Kingdom (NCT06355583)
06 May 2025 Efficacy data from a Phase II trial in Irritable bowel syndrome released by EnteroBiotix
06 May 2025 EnteroBiotix plans a phase IIb trial for Irritable bowel syndrome in May 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com